Ben is Xconomy's Deputy Biotechnology Editor. He is a seasoned business journalist that comes to Xconomy after a nine-year stint at The Deal, where he covered corporate transactions in industries ranging from biotech to auto parts and gaming. Most recently, Ben was The Deal’s senior healthcare writer, focusing on acquisitions, venture financings, IPOs, partnerships and industry trends in the pharmaceutical, biotech, diagnostics and med tech spaces. Ben wrote features on creative biotech financing models, analyses of middle market and large cap buyouts, spin-offs and restructurings, and enterprise pieces on legal issues such as pay-for-delay agreements and the Affordable Care Act. Before switching to the healthcare beat, Ben was The Deal's senior bankruptcy reporter, covering the restructurings of the Texas Rangers, Phoenix Coyotes, GM, Delphi, Trump Entertainment Resorts and Blockbuster, among others. Ben has a bachelor’s degree in English from Binghamton University.
BioMarin Pharmaceutical took a $680 million gamble when it bought Prosensa in 2014 for its experimental Duchenne muscular dystrophy treatment. Drisapersen (Kydrisa) had already failed a Phase 3 trial, but BioMarin... Read more »
Amicus Therapeutics is as familiar with the ups and downs of the drugmaking business as anyone. It has dealt with clinical failures, regulatory setbacks, restructurings, and more over a roughly 15-year... Read more »
All it takes to become an acquisition target in biotech is some promising data. Take Ewing, NJ, and Vancouver-based Celator Pharmaceuticals, which Jazz Pharmaceuticals just agreed to buy this morning for... Read more »
Memorial Day weekend may be fast approaching, but don’t fire up those grills yet: there’s plenty of headlines to dig into first in our biotech trip around the Xconomy network.
In... Read more »
Schizophrenia affects millions of people around the world, which is why any prospective treatment that advances garners close attention. Minerva Neurosciences jumped into the spotlight this morning when an experimental schizophrenia... Read more »
Deborah Dunsire, the former head of Millennium Pharmaceuticals and a well-known Boston biotech veteran, is no longer the CEO of Forum Pharmaceuticals, Xconomy has learned.
Dunsire’s last day at Waltham, MA-based... Read more »
Spero Therapeutics continues to accumulate assets through acquisitions. This morning, the Cambridge, MA-based startup announced a deal to grab rights to a group of experimental antibiotic compounds from Vertex Pharmaceuticals (NASDAQ:... Read more »
The multi-year saga of eteplirsen, a Duchenne muscular dystrophy drug from Cambridge, MA-based Sarepta Therapeutics, will continue to drag on.
Selecta Biosciences became a candidate to go public when a group of crossover investors—institutions that back both public and private companies—piled $38 million into the company in September. Nine months... Read more »
Over the past year, struggling XenoPort has restructured, changed its strategic direction, and reportedly started courting buyers in January. That search looks to have ended today: Arbor Pharmaceuticals has agreed to... Read more »
Back in 2012, Acorda Therapeutics bought a Morrisville, NC, company called Neuronex as part of a plan to branch out beyond its flagship multiple sclerosis drug dalfampridine (Ampyra). Unfortunately, the drug,... Read more »
The race to develop a gene therapy for hemophilia just moved another few feet forward. Spark Therapeutics, which is one of several companies developing a treatment, is the latest to provide... Read more »
Agios Pharmaceuticals rode a wide-ranging partnership with Celgene to a big IPO a few years ago. Today the two companies are partnering once again in a deal that will see Agios... Read more »
It looks like Pfizer is starting to put some of the cash it would have spent on Allergan to use. This morning, weeks after its mega-merger with Allergan fell apart, Pfizer... Read more »
Even though it recently decided to unload a gene therapy for hemophilia into a yet-to-be-named spin-out company, Biogen, one of biotech’s most risk-taking firms, is doubling down on gene therapy for... Read more »
Biotech clusters aren’t built overnight. It takes years of work, a bit of luck, a collaborative atmosphere, and the wherewithal to keep plugging away through the ups and downs. New York... Read more »
Over the past five years, the narrative has changed for life sciences in New York. Biotech investors are, at long last, on the ground in the city looking for deals. High-profile... Read more »
Ariad Pharmaceuticals has been in the midst of a strategic overhaul under a new management regime, and today that effort has resulted in a big transaction. Incyte has just cut a... Read more »
© 2007-2016, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.